Advertisement
Canada markets closed
  • S&P/TSX

    21,875.79
    -66.41 (-0.30%)
     
  • S&P 500

    5,475.09
    +14.61 (+0.27%)
     
  • DOW

    39,169.52
    +50.66 (+0.13%)
     
  • CAD/USD

    0.7279
    -0.0004 (-0.06%)
     
  • CRUDE OIL

    83.44
    +0.06 (+0.07%)
     
  • Bitcoin CAD

    86,470.96
    +266.42 (+0.31%)
     
  • CMC Crypto 200

    1,343.59
    +41.52 (+3.19%)
     
  • GOLD FUTURES

    2,341.60
    +2.70 (+0.12%)
     
  • RUSSELL 2000

    2,030.07
    -17.62 (-0.86%)
     
  • 10-Yr Bond

    4.4790
    +0.1360 (+3.13%)
     
  • NASDAQ

    17,879.30
    +146.70 (+0.83%)
     
  • VOLATILITY

    12.22
    -0.22 (-1.77%)
     
  • FTSE

    8,166.76
    +2.64 (+0.03%)
     
  • NIKKEI 225

    39,631.06
    +47.98 (+0.12%)
     
  • CAD/EUR

    0.6777
    0.0000 (0.00%)
     

With 50% ownership, Fulgent Genetics, Inc. (NASDAQ:FLGT) boasts of strong institutional backing

Key Insights

  • Institutions' substantial holdings in Fulgent Genetics implies that they have significant influence over the company's share price

  • The top 4 shareholders own 52% of the company

  • Insiders own 34% of Fulgent Genetics

A look at the shareholders of Fulgent Genetics, Inc. (NASDAQ:FLGT) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are institutions with 50% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. As a result, a sizeable amount of institutional money invested in a firm is generally viewed as a positive attribute.

ADVERTISEMENT

In the chart below, we zoom in on the different ownership groups of Fulgent Genetics.

Check out our latest analysis for Fulgent Genetics

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Fulgent Genetics?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

Fulgent Genetics already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Fulgent Genetics' historic earnings and revenue below, but keep in mind there's always more to the story.

earnings-and-revenue-growth
earnings-and-revenue-growth

Institutional investors own over 50% of the company, so together than can probably strongly influence board decisions. Fulgent Genetics is not owned by hedge funds. With a 29% stake, CEO Ming Hsieh is the largest shareholder. BlackRock, Inc. is the second largest shareholder owning 13% of common stock, and The Vanguard Group, Inc. holds about 4.8% of the company stock.

Our research also brought to light the fact that roughly 52% of the company is controlled by the top 4 shareholders suggesting that these owners wield significant influence on the business.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

Insider Ownership Of Fulgent Genetics

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Our information suggests that insiders maintain a significant holding in Fulgent Genetics, Inc.. Insiders own US$203m worth of shares in the US$601m company. We would say this shows alignment with shareholders, but it is worth noting that the company is still quite small; some insiders may have founded the business. You can click here to see if those insiders have been buying or selling.

General Public Ownership

The general public-- including retail investors -- own 16% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too.

I like to dive deeper into how a company has performed in the past. You can access this interactive graph of past earnings, revenue and cash flow, for free.

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com